These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33109706)

  • 41. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
    Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H;
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts.
    Balendra R; Jones AR; Al Khleifat A; Chiwera T; Wicks P; Young CA; Shaw PJ; Turner MR; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Feb; 24(1-2):71-81. PubMed ID: 35852375
    [No Abstract]   [Full Text] [Related]  

  • 43. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
    Ismail II; Massoud F; Kamel WA; Al-Hashel JY
    Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
    Kalin A; Medina-Paraiso E; Ishizaki K; Kim A; Zhang Y; Saita T; Wasaki M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):71-79. PubMed ID: 28872919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
    Tomar S; Gupta S; Singal A; Soni R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Staging model for amyotrophic lateral sclerosis in Singapore.
    Tay YT; H Chai JY; Shekh Jabin KB; Ang K
    Singapore Med J; 2022 Jul; 63(7):371-375. PubMed ID: 33472335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
    Park JM; Park D; Kim HJ; Park JS
    BMC Neurol; 2022 Jul; 22(1):260. PubMed ID: 35836136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
    Han HJ; Shin HY; Choi YC; Kim SM; Kim SW
    Redox Rep; 2022 Dec; 27(1):79-84. PubMed ID: 35296219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
    Breiner A; Zinman L; Bourque PR
    CMAJ; 2020 Mar; 192(12):E319-E320. PubMed ID: 32392516
    [No Abstract]   [Full Text] [Related]  

  • 52. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
    Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
    BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
    Dalla Bella E; Bersano E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Filosto M; Giannini F; Spataro R; Lunetta C; Mandrioli J; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Tugnoli V; Verriello L; Volanti P; Furlan R; Nolan JM; Abgueguen E; Tramacere I; Lauria G
    Brain; 2021 Oct; 144(9):2635-2647. PubMed ID: 33905493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study.
    Thakore NJ; Lapin BR; Pioro EP;
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):140-143. PubMed ID: 31450993
    [No Abstract]   [Full Text] [Related]  

  • 58. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A nerve conduction study predicts the prognosis of sporadic amyotrophic lateral sclerosis.
    Imai E; Nakamura T; Atsuta N; Nakatochi M; Suzuki M; Harada Y; Nakamura R; Hayashi N; Sobue G; Katsuno M
    J Neurol; 2020 Sep; 267(9):2524-2532. PubMed ID: 32367295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.